Interview: Luis Almeida, CEO, Luzitin, Portugal
Luis Almeida, CEO of Luzitin Portugal, talks about the Innovation of the Decade award Luzitin received for its patented technology, what exactly is so unique and innovative about this technology,…
Luzitin, S.A. is an early-stage pharmaceutical company focused on investigating and developing innovative compounds to be used in Photodynamic Therapy (PDT) or Photodiagnosis (PDx) of cancer or other diseases, thus contributing to the human wellness.
Luzitin emerged as a spin-off company from an R&D partnership between Bluepharma, S.A. and the University of Coimbra, Portugal. The Luzitin’s starting intellectual property is a series of new photosensitizing drugs licensed-in from the University of Coimbra. In March 2011, these new photosensitizers have been awarded the INVENTA Prize, which honoured the most relevant Portuguese invention of the 2001-2010 decade.
Luzitin’s shareholders are Bluepharma, S.A., a venture capital firm (Portugal Ventures, S.A.), and the inventors of the patented drugs. Luzitin’s headquarters are located at S Martinho do Bispo, Coimbra, Portugal. Luis Almeida, MD, PhD (Chief Executive Officer), Luis Arnaut, PhD (Chief Scientific Officer), and Sérgio Simões, PharmD, PhD (Chairman), compose the Management Team (MT). All have over 20 years of experience in their fields, and altogether they cover all disciplines involved in drug R&D from bench to bedside.
Luzitin’s long-term goal is to become a leader in PDT or PDx of cancer and other selected indications by providing innovative products and services, and partnering with other companies and public research institutions to bring new products to market.
Luzitin is committed to reach proof-of-concept clinical trials (phase II) and afterwards to negotiate licensing terms with a pharmaceutical company to further co-develop and co-market its compounds.
Contact:
Luzitin, SA
Edifício Bluepharma – Rua da Bayer – S. Martinho do Bispo
3045-016 Coimbra
PORTUGAL
Phone: +351 239 800 300
Fax: +351 239 800 333
www.luzitin.pt
Luis Almeida, CEO of Luzitin Portugal, talks about the Innovation of the Decade award Luzitin received for its patented technology, what exactly is so unique and innovative about this technology,…
Fransisco Velez, Founder and Director General of toLife, discusses the challenges facing generics companies in Portugal today, and his ambitions to further grow his company over the years to…
João Madeira, General Manager of Mylan Portugal provides an overview of the state of generics in Portugal today, discussing structural issues related to Portugal’s low generic medicines penetration, ways to…
Hernâni Sério, General Manager of the Portuguese affiliate, Fresenius Kabi, discusses the challenges of the hospital market, as well as his company’s strategic positioning in a market with few competitors…
As a company focused entirely on innovation, Janssen has remained dedicated to bringing groundbreaking new products to Portugal, ensuring access in Portugal is as stellar as anywhere else. Gisella Dante,…
Paulo Lilaia, CEO of Generis Portugal give an insight into the role of generics in the Portuguese marketplace as well as his company’s strategy to expand in both the local…
Cristina Campos, CPO Head and Country President of Novartis Portugal talks about the challenges surrounding market access in Portugal, as well as the affiliate’s strong investments in the country to…
Mario Martins, General Manager of Cegedim Portugal discusses the changes that his affiliate has made to adapt to the new realities of the Portuguese marketplace, and explains how a business…
Nelson Pires, General Manager of Jaba Recordati, the Portuguese affiliate of the Recordati Group, outlines the affiliate’s expansion into the PALOPS markets and demonstrates how the company has grown during…
Despite Portugal’s economic woes, some local companies have been able to adjust accordingly and succeed in this environment. Tecnifar is no exception. The company’s CEO, António Chaves Costa, talks about…
Joaquim Cunha, Executive Director of Health Cluster Portugal (HCP), emphasizes Portugal’s need to discover niches in which the country can excel and compete globally, while rebranding its image around the…
Nuno Arantes-Oliveira, President of P-BIO, Portugal’s Biotechnology Industry Organization, the country’s sole association for biotechnology companies, discusses the state of the biotech industry today in Portugal, and the ways in…
Pedro Ferraz da Costa, CMO Iberfar’s president, discusses generic competition in Portugal, his company’s expansion into Angola and southern Africa, and the company’s competitive advantages with its various subsidiaries. There…
See our Cookie Privacy Policy Here
